Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2025 Jul;72(7):e31750.
doi: 10.1002/pbc.31750. Epub 2025 May 2.

Associations Between Pain Scores and Opioid Doses With Emergency Department Disposition and Return Visit Rates in Children With Sickle Cell Disease

Affiliations
Multicenter Study

Associations Between Pain Scores and Opioid Doses With Emergency Department Disposition and Return Visit Rates in Children With Sickle Cell Disease

Keli D Coleman et al. Pediatr Blood Cancer. 2025 Jul.

Abstract

Rapid treatment and frequent reassessment of pain are key components of treatment guidelines for acute sickle cell disease (SCD) pain. Few studies, however, report the associations between emergency department (ED) pain scores, number of ED opioid doses, receipt of an opioid prescription, ED visit disposition, or ED return visits. This seven-site retrospective cohort study analyzed 4983 ED visits by children with SCD pain using electronic health record data from the Pediatric Emergency Care Applied Research Network Registry. ED pain scores included initial, last, and change in scores (initial minus last), measured on a 0-10 scale. Dispositions of discharge and hospital admission were included. Modified Poisson regression and the Cochran-Armitage test of trend were used for analysis. The median (IQR) initial pain score was 8.0 (6-10); last pain score was 5.0 (2-8); and median decrease was 2.0 (0-5). In multivariable analysis, last pain score was the best predictor of disposition. For the return visit analyses, of the 2377 visits discharged at index ED visit, 29% returned within 14 days. Higher initial and last ED pain scores were associated with increased return visits. Children with no opioid discharge prescription and ≥3 ED opioid doses had a return visit rate of 36% compared to 22% if the child received an opioid prescription and only one ED opioid. Increasing discharge opioid prescriptions and targeting interventions for those who receive multiple ED opioid doses could decrease return visits.

Keywords: emergency department; pain score; sickle cell.

PubMed Disclaimer

Conflict of interest statement

Claudia R. Morris: CSL Behring: consultancy; UCSF Benioff Children’s Hospital Oakland: patents and royalties; inventor of IP generating royalties; Trility: membership in scientific advisory board; Food as Medicine Therapeutics, LLD: executive director, founder, and equity holder in private company. Andrew D. Campbell: Novartis: consultancy; Global Blood Therapeutics: consultancy; Agios: consultancy; Forma: consultancy; Vertex: consultancy. Robert I. Liem: BlueBird Bio: research funding; GBT: research funding; Editas: research funding; NHLBI: research funding. Charles T. Quinn: Aruvant: research funding; Emmaus Medical: research funding. Alexis A.Thompson: Biomarin: research funding; Baxalta: research funding; CRISPR/Vertex: consultancy, research funding; Bristol Myers Squibb: consultancy, research funding; bluebird bio Inc.: consultancy, research funding; Beam: research funding, consultancy; Agios: consultancy; Editas: research funding, consultancy; Global Blood Therapeutics: equity holder in publicly traded company, membership on an entity’s board of directors or advisory committees; Novartis: research funding. Anthony Villella: CRISPR Therapeutics: consultancy. Allison A. King: Cigna: consultancy; UptoDate: royalties. David C. Brousseau: CSL Behring: consultancy.

Figures

FIGURE 1 |
FIGURE 1 |
Study flow diagram. 1: Primary billing diagnosis for SCD (ICD-10 = D57,* except sickle cell trait) or a chief complaint of sickle cell pain event or sickle cell fever and received at least one parenteral opioid pain medication in the ED. Visits from January 2017 through November 2021. 2: Visits could be ineligible due to more than one exclusion criteria. 3: Left against medical advice, left without being seen, or missing disposition.
FIGURE 2 |
FIGURE 2 |
Association between ED opioid doses administered/receipt of an opioid prescription at discharge and 14-day ED return visit rates.

References

    1. Brousseau DC, Panepinto JA, Nimmer M, et al. , “The Number of People With Sickle-Cell Disease in the United States: National and State Estimates,” American Journal of Hematology 85, no. 1 (2010): 77–78. - PubMed
    1. Hassell KL, “Population Estimates of Sickle Cell Disease in the US,” American Journal of Preventive Medicine 38, no. 4 suppl (2010): S512–S521. - PubMed
    1. Brandow AM, Zappia KJ, and Stucky CL, “Sickle Cell Disease: A Natural Model of Acute and Chronic Pain,” Pain 158, no. Suppl 1 (2017): S79–S84. - PMC - PubMed
    1. Kidwell K, Albo C, Pope M, et al. , “Characteristics of Sickle Cell Patients With Frequent Emergency Department Visits and Hospitalizations,” PLOS One 16, no. 2 (2021): e0247324, 10.1371/journal.pone.0247324. - DOI - PMC - PubMed
    1. Meier ER and Miller JL, “Sickle Disease in Children,” Drugs 72, no. 7 (2012): 895–906. - PMC - PubMed

Publication types

MeSH terms

Substances